J Extra Corpor Technol
Volume 46, Number 1, March 2014
|Page(s)||94 - 97|
|Published online||15 March 2014|
Bivalirudin in Venovenous Extracorporeal Membrane Oxygenation
Address correspondence to: Aman Jyoti, MD, Department of Cardiac Anaesthesia, Dharma Vira Heart Centre, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi-110060, India. E-mail: email@example.com
Accepted: 7 January 2014
Optimal anticoagulation plays a pivotal role in successful outcome of extracorporeal membrane oxygenation (ECMO). Heparin has been the anticoagulant of choice owing to its advantages like easy monitoring and reversibility. However, if heparin resistance is encountered, one has to decide whether to treat heparin resistance with fresh-frozen plasma or antithrombin concentrates or to choose one of the heparin alternatives for anticoagulation. We report a case of heparin resistance resulting from antithrombin III deficiency in a patient on venovenous ECMO, in which anticoagulation was managed with bivalirudin. The dose of bivalirudin for anticoagulation in ECMO has not been standardized and different authors have reported different doses. We found a bivalirudin dose of .1–.2 mg/kg/h to be adequate to maintain a target activated clotting time of 200–220 seconds. Platelet counts were stable throughout and no major bleeding or thrombotic complications took place. We found bivalirudin to be a feasible and effective anticoagulant and safe to use for long durations in ECMO without any major complications.
Key words: antithrombin III deficiency / bivalirudin / extracorporeal membrane oxygenation / heparin resistance
© 2014 AMSECT
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.